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Abstract
Background: Invasive aspergillosis (IA) is a major cause of morbidity and mortality in profoundly neutropenic patients, so early 
  diagnosis is mandatory.
Aim: Consecutive patients with hematological malignancies undergoing intensive chemotherapy were screened for IA with two   different 
methods which were compared.
Methods: From October 2000 to August 2003 we tested 1311 serum samples from 172 consecutive patients with a polymerase chain 
reaction assay and between April 2005 and April 2008 we tested 806 serum samples from 169 consecutive patients with a Galactomannan 
(GM) test. Bronchoalveolar (BAL) samples were obtained whenever the patient’s condition allowed and tested with either method.
Results: The serum PCR assay had a sensitivity of 75.0% and a specificity of 91.9% and the serum GM assay had a sensitivity of 87.5% 
and a specificity of 93.1%, (P . 0.05). The presence of two or more consecutive positive serum samples was predictive of IA for both 
assays. BAL GM/PCR was positive in some patients without serum positivity and in patients with 2 or more positive serum GM/PCR.
Conclusions: No significant differences between the 2 serum tests were found. The GM assay has the advantage of being standardized 
among several laboratories and is incorporated in the criteria established by the European Organization for Research and Treatment 
of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycosis Study 
Group (EORTC/MSG), however is much more expensive. BAL GM and PCR sampling aids in IA diagnosis but needs further validation 
studies to differentiate between colonization and true infection in cases where serum GM or PCR are negative.
Keywords: hematological malignancies, intensive chemotherapy, neutropenia, invasive aspergillosis (IA), early diagnosis, serum   
PCR and Galactomannan (GM)Lopes da Silva et al
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Introduction
Despite  the  latest  therapeutically  advances,  IA  is 
still a major cause of morbidity and mortality among 
hematological patients under intensive chemotherapy 
or hematopoietic stem cell transplantation (HSCT).1,2
Diagnosis of IA is difficult and challenging.   Clinical 
manifestations are non specific and IA proof depends on 
invasive procedures that usually the patient does not tol-
erate.3 Thus, antifungals have been used empirically for 
decades in refractory neutropenic fever with high costs 
and toxicity.4–6 Non invasive methods for early diagno-
sis are of great value if a pre-emptive approach is to be 
chosen.7,8 The detection of the GM antigen, a constituent 
of polysaccharide fungal cell wall and the detection of 
fungal DNA by a PCR method9 have been developed 
with the aim to quickly screen patients for IA.
We compared the value of the two screening meth-
ods (GM and PCR) in similar patients (hematologi-
cal malignancies and profoundly neutropenic) in the 
same conditions (same open ward with HEPA filters). 
Between 2000 and 200310 serum PCR assay was per-




From  October  2000  to August  2003,  172  patients 
(median age 50 years) with acute myeloid leukemia 
(AML)  (119  Patients),  acute  lymphoblastic  leuke-
mia  (ALL)  (26  patients)  underwent  intensive  che-
motherapy as induction or consolidation therapy and 
27 patients received high dose chemotherapy in an 
autologous  hematopoietic  stem  cell  transplantation 
(auto-HSCT) setting. All patients were screened by 
PCR twice a week since admitted in the ward.
Between April 2005 and April 2008, 169 patients 
(median age 55 years) with AML received intensive 
chemotherapy (107 patients) as induction or consoli-
dation  therapy  and  62  patients  received  high  dose 
chemotherapy for auto-HSCT. Again all patients were 
screened twice a week for GM analysis.
Patients’  characteristics  are  summarized  in 
Table 1.
Definitions
Febrile episodes were classified according to EORTC 
criteria as fever of unknown origin, fever with   clinical 
documentation  and  fever  with    microbiological 
documentation.
Fever  was  defined  as  two  or  more  consecutive 
measurements of axillary temperature $38 °C and 
neutropenia as a neutrophil count below 500/mL for 
at least 7 days.
Fungal  infections  were  classified  according  to 
EORTC/MSG revised consensus:11 Proven IA requires 
culture and identification i.e. histopathology or direct 
microscopic examination of a specimen obtained by 
needle aspiration or biopsy in which “hyphae” are 
seen accompanied by evidence of associated tissue 
damage and recovery of a mould by culture of a spec-
imen obtained by a sterile procedure from a normally 
sterile and clinically or radiologically abnormal site 
consistent with an infectious disease process.
Probable IA relies on 3 elements, namely, a host 
factor that identifies the patients at risk (neutrope-
nia ,500/mL for .10 days, HSCT, prolonged use 
of corticosteroids, treatment with T-cell immunosup-
pressors);  clinical  signs  and  symptoms  consistent 
with the disease entity (lower respiratory tract fungal 
disease with presence of 1 of the following 3 signs on 
CT: dense well-circumscribed lesions with or without 
a halo sign, air-crescent sign, cavity; and mycologi-
cal criteria: direct tests (cytology, direct microscopy 
or culture) showing the presence of mould in spu-
tum, BAL fluid, bronchial brush) and indirect tests 
  (detection of antigen or cell-wall constituents, such 
as GM antigen in plasma, serum or BAL fluid). Cases 
that meet the criteria for a host factor and a clinical 
criterion but for which mycological criteria are absent 
are considered possible IA.
Table 1. patients’ characteristics.
  pcR GM
N° patients 172 169
Median age/range (years) 50/16–77 55/15–75
Male/female 102/70 87/82
N° neutropenic episodes 418 321
Median neutropenia (days) 26 11
Treatment episodes
  - Induction chemoterapy 141 175
  - Consolidation chemoterapy 127 59
  - reinduction chemoterapy 123 25
  - Autologous hSCT 27 62
Abbreviations: hSCT, hematopoietic stem cell transplantation; pCr, 
polymerase chain reaction; GM, galactomannan.Invasive Aspergillosis
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study Design and Methods
Peripheral blood samples from patients were screened 
twice weekly for both methods since admission in 
the ward. If a positive value was obtained the patient 
would  be  screened  everyday  for  three  consecutive 
days in the first week and then twice weekly again. 
Blood samples were collected using 5-ml vacutainer 
tubes with EDTA to minimize chances of environ-
mental contamination. The whole blood was asep-
tically transferred using a disposable pipette with a 
filtered tip into a centrifuge tube after careful removal 
of the vacutainer’s rubber stopper. Besides that, to 
avoid false GM positives, blood samples were always 
scheduled to be drafted before antibiotics adminis-
tration. As for PCR assay, in order to minimize false 
positives, from contamination from the environment 
or contamination of reagents by fungal DNA, pro-
cedures were done in a flow cytometry chamber and 
reagents were submitted periodically to amplification 
procedure  with  fungal  specific  probes  as  negative 
controls in parallel with patient’s samples.
Serum and BAL pCr assay
Blood samples, BAL samples, fungal DNA extraction 
and PCR conditions were performed as described.10,12 
The whole process of amplification (denaturation at 
94 °C for 5 min, 35 cycles of 94 °C for 45s, 62 °C 
for 1 min and 30s, 72 °C for 2 min, ending in a final 
elongation step at 72 °C for 10 min ) was done using 
Taq polymerase (Gibco BRL) and pan-fungal primers 
(forward 5´-ATTGGAGGGCAAGTCTGGTG-3´ and 
the reverse 5´-CCGATCCCTAGTCGGCATAG-3´)13   
that bind to the conserved regions of the fungal 18S 
rRNA gene sequence, yielding PCR- amplified prod-
ucts of 197 bp through a 1,8% agarose gel stained with 
ethidium bromide and UV photographed (Kodak 120 
camera system). Established PCR negative and posi-
tive controls were used in every assay. Positive con-
trols were obtained from DNA extracted from mould 
cultured in the laboratory of microbiology especially 
for the purpose. Negative controls were established 
as stated above.
Serum and BAL GM assay
An  enzyme-linked  immunosorbent  assay-based  kit 
is commercially available as the Platelia Aspergillus 
GM  EIA  (Bio-Rad  Laboratories,  Redmond,  Wash) 
and was cleared by the FDA for diagnostic use in 
May  2003.  It  is  an  immunoenzymatic  sandwich 
microplate  assay  that  uses  monoclonal  antibodies 
that bind to side-chain residues of the GM molecule. 
A  sandwich  enzyme  immunoassay  format  is  used 
for detection. The Platelia Aspergillus GM EIA was 
used to quantify GM in accordance with the manu-
facturer’s instructions. Briefly, after thawing, serum 
samples were mixed well, and 300 uL of each sample 
was added to 100 uL of 4% EDTA treatment solu-
tion, boiled for 3 min, and centrifuged at 10,000 g for 
10 min. Supernatant was added to a reaction mixture 
containing conjugated anti-GM EB-A2 antibody, and 
the mixture was incubated in microtiter plates pre-
coated with the same antibody (EB-A2) for 90 min at 
37 °C and then incubated again with 200uL of tetram-
ethylbenzidine solution for an additional 30 min in 
the  dark.  Reactions  were  stopped  with  100  uL  of 
1.5 M sulfuric acid, and optical densities (ODs) at 
450 and 620 nm were read. Positive and negative 
controls (provided in the kit) were included in each 
assay.  Results  were  recorded  as  an  index  relative 
to the OD of the threshold   control (GM index OD 
  sample/OD threshold control). Both serum and BAL 
GM samples were considered   positive when index 
value was $0.5 ng/mL.14–16
Complementary diagnostic procedures
Chest CT scans were performed early in the course of 
neutropenic fever refractory to antibiotics and when a 
positive sign (dense well-circumscribed lesions with 
or without a halo sign, air-crescent sign and cavity) 
was present, sequential CT scans were repeated until 
response.  Bronchoscopy  with  BAL  was  performed 
whenever  necessary  and  if  the  patient’s  condition 
allowed. A total of two 20 mL aliquots of sterile 0.9% 
saline was instilled into each affected bronchus and 
aspirated into sterile collection traps.
Antifungal treatment
No antifungal prophylaxis was given to our patients 
in either period.
Prompt  antifungal  therapy  was  initiated  if 
patients met the criteria of proven, probable or pos-
sible IA as stated above. Deoxycholate amphoteri-
cin  (1  mg/kg/day)  or  Liposomal  B  amphotericin 
(3 mg/kg/day) was used as first line therapy in the PCR Lopes da Silva et al
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study period while Voriconazole (6 mg/kg q 12 hours 
intravenous on day 1 and then 4 mg/kg q 12 hours 
intravenous on day 2 onwards) was the antifungal of 
choice during the GM study period.
Statistical analysis
Sensitivity  and  specificity  were  calculated  for  the 
serum GM and the PCR assay with standard bino-
mial  probabilities  with  a  95%  confidence  interval 
(CIs). For the differences between both methods the 
P   values were calculated by Fisher’s exact test.
Results
The total number of samples of PCR and GM tested 
according to febrile episodes and the numbers of posi-
tive samples are shown in Table 2. The PCR screening 
was performed in an average of 3.14 samples per epi-
sode and in an average of 6.8 samples per patient. The 
GM assay was performed in an average of 2.51 sam-
ples per episode and an average of 6.76 samples per 
patient. In the PCR study, 60 among 151 episodes of 
fever  with  clinical  documentation  corresponded  to 
pneumonia, of which 20 fulfilled the requirements 
for IA (2 Proven/18 Probable) according to EORTC/
MSG criteria. In the GM study 40 among 121 epi-
sodes of neutropenic fever were pneumonia of which 
8 had IA criteria (2 Proven/6 Probable).
All patients with 2 or more consecutively GM/PCR 
positive serum samples developed an IA. Patients with 
2 or more positive serum GM also had a positive BAL 
GM test but some patients without positive serum 
GM had positive BAL GM. PCR was equally per-
formed on BAL samples and matched PCR positive 
serum samples whenever performed. However some 
cases without serum PCR positivity were BAL PCR 
positives. A single patient with persistently negative 
serum GM and BAL GM had a proven IA   diagnosis. 
Serum PCR and GM results analysis according to the 
final diagnosis using the EORTC/MSG criteria are 
detailed in Table 3.
Antifungal therapy was initiated during both study 
periods either in the presence of at least 2 consecu-
tive positive PCR or GM results or in the presence 
of strong clinical evidence even when both PCR and 
GM were negative. PCR negativation and GM index 
gradual reduction with normalization were observed 
and matched CT scan response.
PCR screening predicted the appearance of IA by 
a median of 17 days and GM predicted by a median 
of 5 days. The PCR study had a sensitivity of 75% 
and the serum GM method had a sensitivity of 87.5% 
(P = 0.64). The specificity of both tests was 91.9% 
and 93% respectively as detailed in Table 4.
Discussion
IA has a high mortality rate (60%–90%) explained 
by the diagnostic delay due to the limitation of cur-
rent diagnostic tests, so early IA diagnosis in patients 
undergoing intensive chemotherapy or HSCT remains 
a significant challenge to overcome. In the majority of 
cases the typical clinical signs according to EORTC/
MSG criteria are non-visible and often develop too 
late in the course of infection.3 Thus chest radiography 
is too insensitive to diagnose IA at an early stage and 
chest CT scan, although an important diagnostic tool 
that has played a pivotal role in IA diagnosis, remains 
unspecific, since initial nodular lesions surrounded by 
areas of lower attenuation “halo sign” and late cavita-
tions following neutrophil recovery creating the “air 
crescent sign”, may be due to other species of fungi 
(Zygomycetes,  Fusarium,  Scedosporium)  and  even 
bacteria (Pseudomonas aeruginosa)17,18 and in several 
occasions these features are not present at all. Fur-
thermore, blood cultures are not useful since they are 
Table 2. Samples of GM and PCR tested according to classification of febrile episodes.
Classification n° episodes Tested samples positive tests
  pcR/GM pcR/GM pcR/GM
Without fever 39/13 80/28 1/3
Unknown origin 75/68 210/113 10/0
Clinical documentation 151/121 602/337 22/34
Microbiological documentation 153/119 419/328 24/17
Abbreviations: pCr, polymerase chain reaction; GM, galactomannan.Invasive Aspergillosis
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often negative even in disseminated infection and take 
too long to become positive (median 15 days). Tissue 
biopsy  and  fluids  obtained  by  invasive  procedures 
(transthoracic percutaneous needle aspiration, video 
assisted thoracoscopic biopsy, bronchoscopy) consid-
ered the cornerstone of diagnosis of this entity are not 
always possible to obtain because the diagnostic pro-
cedure can not be performed directly in patients who 
are not fit (hypoxemic, hemodynamically instable and 
thrombocytopenic).11,19 Even if feasible, the histopa-
thology examination and culture may be falsely nega-
tive because the invasive procedure could not reach 
the infected area or the patient is already receiving 
systemic antifungal therapy. Another issue regarding 
cultural exam is the slowness or absence of growth 
of fungal isolates.20 It is clearly urgent the need to 
search  for  an  alternative  diagnostic  approach,  that 
may be specific, sensitive and quick. This alone or 
in complement with radiological tools may improve 
early diagnosis of IA. Delay is as we know tragic for 
outcome and most centres develop empiric strategies 
to overcome the time delay but at toxicity expenses 
that  are  also  highly  expensive.  The  non-invasive 
serum markers Aspergillus GM test, PCR detection 
for fungal DNA and 1,3-β-D-glucan test can over-
come some of these problems. For budget reasons 
the majority of the centres have implemented one test 
only and sometimes it is hard to choose. Both GM 
and 1,3-β-D-glucan are available kits, standardized 
which allow for comparison between centres but very 
expensive and only screen for Aspergillus spp. On the 
other hand, pan-fungal PCR is broader, it detects any 
fungal infection, less expensive and very easy and 
quick to perform.
The aim of this study was to compare two methods 
for IA screening, serum PCR versus GM in similar 
cohorts of patients. Our results showed that the GM 
assay sensitivity was slightly higher than that of PCR 
(87.5% and 75% respectively), but the difference was 
not statistically significant which may be explained 
by the method characteristic, since a pan-fungal PCR 
screening will detect any other fungal infection that 
when validated for IA criteria will underestimate IA 
infection. PCR was highly specific (91, 9%) as the 
GM assay (93.0%).
An important point to mention is that in our study, 
2  consecutive  positive  serum  samples,  with  both 
methods, were associated with the development of IA. 
A single positive sample was not as highly predictive. 
This strengthens the importance of requiring 2 con-
secutive serum positive results as a clear indicator of 
IA21 by minimizing the risk of false positives.
In  this  study  patients  with  2  or  more  serum 
GM/PCR positive samples who we were able to per-
form a bronchoscopy had also positive BAL results 
reinforcing the notion that BAL GM/PCR determina-
tion is a sensitive and specific test for diagnosis of 
proven and probable IA in whatever fluid or whole 
blood and may be helpful to confirm diagnosis of 
IA in these cases.22–24 The BAL GM/PCR positivity 
obtained in those patients without serum GM/PCR 
positivity could be due to a very early diagnosis i.e. 
before the Aspergillus could breach the alveolar cap-
illary  surface  and  enter  the  bloodstream. The  GM 
cut-off of 0.5 ng/mL used in our laboratory increases 
the sensitivity at the cost of lowering the specific-
ity25  but  was  agreed  as  the  ideal  threshold  by  the 
EORTC/MSG criteria.
Another  observation  worthy  of  mention  is  that 
PCR negativation or GM index normalization during 
Table 3. PCR and GM results and final diagnosis   according 
to eOrTC-MSG.
pcR With IA Without IA Total patients
positive 15 14 29
Negative 5 159 164
Total patients 20 173 193
GM With IA Without IA Total patients
positive 7 11 18
Negative 1 150 151
Total patients 8 161 169
Abbreviations: pCr, polymerase chain reaction; IA, invasive aspergillosis.
Table  4.  Sensitivity  and  specificity  of  GM  and  PCR 
assays.
  pcR/(95% cI) GM/(95% cI)
Sensitivity % 75,0/(50,6–90,4)  87,5/(46,7–99,3) 
Specificity %  91,9/(86,5–95,3) 93,1/(87,8–96,4)
ppV % 51,7/(32,9–70,1) 38,9/(18,3–63,9)
NpV % 97,0/(92,7–98,9) 99,3/(95,8–99,8)
Abbreviations: pCr, polymerase chain reaction; GM, galactomannan; 
ppV, positive predictive value; NpV, negative predictive value.Lopes da Silva et al
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antifungal  treatment  was  associated  with  a  better 
  clinical  outcome  and  survival  proving  that  both 
    metho    ds are useful for therapy monitoring. Both GM 
and PCR methods are simple, safe, fast and reliable. 
Both have acceptable sensitivity and specificity and 
can be used to decide to start pre-emptive antifungal 
therapy. Both tests enable us to follow up the evo-
lution of the disease by monitoring the efficacy of 
the therapy chosen and change to alternative anti-
fungal drugs in case of no response but antifungal 
treatment duration should be determined not solely 
by normalization of serum GM/PCR but also by the 
clinical  and  radiologic  findings  resolution,26,27  in 
fact, survival is significantly better in patients who 
become GM negative.28,29 In our study PCR based 
approach was identical but more prospective stud-
ies are needed to validate these results.30,31 The PCR 
assays have not yet been standardized and remain 
investigational, although coordinated efforts through 
the EORTC/MSG to address the issue of standard-
ization of nucleic acid–based testing are ongoing.32,33 
Quantitative techniques in particular real-time PCR 
may improve sensitivity.34,35 The advantage of a com-
mercial PCR diagnostic kit would allow for standard-
izing methodology between centres but will increase 
costs.36,37 PCR results are not interfered by diet or 
antibiotics administration as with GM tests where 
false positives can be caused by several items such 
as  the  passage  of  dietary  through  injured  mucosa 
(pasta, rice, canned vegetables),38 by the administra-
tion of antibiotics like piperacillin-tazobactam and 
amoxicillin-clavulanic acid,39–41 by Bifidobacterium 
lipoteichoic  acid42  and  some  other  fungal  species 
including  Penicillium,  Paecilomyces,  Histoplasma 
and Geotrichum43–45 and by gastrointestinal chronic 
graft-versus-host  disease.46  Furthermore,  variables 
that reduce the fungal load and thus the circulating 
GM levels, such as mould-active antifungal prophy-
laxis decrease the assay performance.47–49 BAL GM 
is a valuable adjunctive diagnostic tool generally not 
hampered by these variables but the lack of wide-
spread experience and consensus on optical density 
(OD)  cut-offs  and  standardized  method  of  collec-
tion limits at some point its utility.50 An electrolyte 
solution (containing sodium gluconate produced by 
Aspergillus niger fermentation) used for bronchoal-
veolar lavage (BAL) can also cause false positives.51
Delayed  IA  diagnosis  is  associated  with  poor 
prognosis  and  high  mortality  rates. Antifungal  ther-
apy should be initiated as soon as IA is suspected i.e. 
at the stage of possible infection, because it improves 
outcome,52,53 reduces the use of antibiotics and anti-
fungals, is less toxic and is cost-effective. Non-culture 
based  biomarkers  could  expand  our  capabilities  to 
establish early and specific diagnosis for IA or even 
help with assessment of response to antifungal therapy. 
GM is for the time being a better option. To improve 
its diagnostic accuracy the number of samples per epi-
sode of neutropenia should be increased. Ideally the 
same patient should be tested by PCR and GM simul-
taneously at the same time but we doubt that such a 
study will ever be performed routinely since it implies 
more costs and the majority of the departments have to 
answer to tight budgets.54,55
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